GlassScriptPhysician profile
Dan A Boggus
NPI 1669419248
$4,369.38
in general payments reported to CMS, 2019-2025
29 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $973 · 2021: $849 · 2022: $579 · 2023: $502 · 2024: $788 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $809.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $702.13 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $684.23 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $494.67 | 2019-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $257.86 | 2020-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $169.82 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $169.14 | 2019-2023 | |
| Amgen INC. | $145.42 | 2020-2025 | Otezla, Repatha, Repatha |
| Genentech USA, INC. | $133.31 | 2019-2022 | |
| Allergan, INC. | $110.45 | 2020 | |
| Gilead Sciences, INC. | $99.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $70.37 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $68.43 | 2019-2025 | Capvaxive |
| Abbvie INC. | $59.57 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.93 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $46.29 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $44.77 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $31.57 | 2020-2021 | |
| Dexcom, INC. | $25.19 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $25.13 | 2025 | The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $23.17 | 2022 | |
| Ironshore Pharmaceuticals INC. | $22.31 | 2019 | |
| Bausch Health US, LLC | $21.17 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.87 | 2022 | |
| Abbott Laboratories | $20.73 | 2022 | |
| Amarin Pharma, INC. | $16.92 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.95 | 2020 | |
| Radiometer America, INC | $15.90 | 2022 | |
| Tris Pharma INC | $15.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Boggus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.